Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic ...
In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...
PSMA radioligand therapy is associated with significant reductions in PSA levels among select patients with metastatic prostate cancer, suggesting tumor responses. Prostate-specific membrane antigen ...
Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, ...
PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...
News-Medical.Net on MSN
New trial aims to improve both survival and quality of life for men with advanced prostate cancer
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...
Prostate-specific membrane antigen (PSMA)-PET appeared to cut the risk for treatment failure by half in patients receiving salvage radiotherapy (RT) after radical prostatectomy, without increasing ...
Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533 To our knowledge, this is the first phase II randomized trial ...
Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback